APA (7th ed.) Citation

Harter, P., Bogner, G., Chiva, L., Cibula, D., Concin, N., Fotopoulou, C., . . . Vergote, I. (2024). Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer. Bulletin du cancer, 111(3), . https://doi.org/10.1016/j.bulcan.2023.02.011

Chicago Style (17th ed.) Citation

Harter, Philipp, et al. "Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Epithelial Ovarian Cancer." Bulletin Du Cancer 111, no. 3 (2024). https://doi.org/10.1016/j.bulcan.2023.02.011.

MLA (9th ed.) Citation

Harter, Philipp, et al. "Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Epithelial Ovarian Cancer." Bulletin Du Cancer, vol. 111, no. 3, 2024, https://doi.org/10.1016/j.bulcan.2023.02.011.